Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.

Related Articles

Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.

Lung Cancer. 2016 Dec;102:42-43

Authors: Gibelin C, Avrillon V, De La Fouchardiere A, Mc Leer-Florin A, Lantuejoul S, Fayette J

Abstract
Non-small cell lung cancers (NSCLCs) have molecular characterization and most druggable genetic and molecular abnormalities, such as EGFR, ERBB2 and BRAF mutations, and ALK and ROS1 rearrangements, have been observed in a subset of adenocarcinomas or large cell carcinomas [1]. Even if these abnormalities are seldom detected in squamous cell carcinomas (SQCC), some rare cases of SQCC have been reported to harbor EGFR, ROS1 or ALK genetic alterations with in some cases a response to targeted therapies [2,3]. Here, we describe a patient with a SQCC harboring ROS1 rearrangement and a response to the target therapy, crizotinib.

PMID: 27987587 [PubMed - in process]

http://ift.tt/2h4AHOS